Código QR (código de barras bidimensional)

Treatment with immune checkpoint inhibitors after EGFR‐TKIs in EGFR‐mutated lung cancer

Abstract Background Epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs) have become the gold standard for EGFR‐mutated non‐small cell lung cancer (NSCLC) treatment. Immune checkpoint inhibitors (ICIs) have been developed for the treatment of several malignancies, including lung c...

Fuld beskrivelse

Na minha lista:
Principais autores: Takashi Ito, Hiromi Nagashima, Masachika Akiyama, Yu Utsumi, Hideomi Sato, Shinji Chiba, Mayu Sugai, Kenji Ube, Yoshiaki Mori, Kana Watanabe, Tatsuro Fukuhara, Makoto Maemondo
Format: Artigo
Sprog:Inglês
Udgivet: Wiley 2022-02-01
Serier:Thoracic Cancer
Fag:
EGFR mutation
EGFR tyrosine kinase inhibitor
immune checkpoint inhibitor
L858R mutation
non‐small cell lung cancer
Online adgang:https://doi.org/10.1111/1759-7714.14267
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker